- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lorundrostat Significantly Lowers Blood Pressure in Resistant Hypertension: Study

USA: A recent clinical trial has shown that Lorundrostat, a novel aldosterone synthase inhibitor, significantly lowers blood pressure in patients with uncontrolled and treatment-resistant hypertension. The study, which assessed both the efficacy and safety of lorundrostat, presents encouraging prospects for individuals who have struggled to achieve blood pressure control with conventional antihypertensive treatments.
The findings from this double-blind, randomized trial were published online in the New England Journal of Medicine.
Hypertension, often referred to as high blood pressure, is a prevalent condition that can lead to severe cardiovascular events if not adequately controlled. While several medications are available to manage hypertension, some patients, particularly those with treatment-resistant hypertension, remain inadequately controlled, posing a challenge for both healthcare providers and patients.
Aldosterone dysregulation contributes to hypertension by affecting sodium retention and fluid balance. Lorundrostat, an aldosterone synthase inhibitor, offers a potential solution, but its efficacy and safety in hypertensive patients remain underexplored. To fill this gap, Luke J. Laffin, Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, and colleagues focused on evaluating Lorundrostat's effectiveness and safety, particularly in those with uncontrolled or treatment-resistant hypertension.
For this purpose, the researchers conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients on two to five antihypertensive medications with office blood pressure readings of 140/90 mm Hg or higher. After a 3-week standardized treatment phase, those with a 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomized to receive either a placebo, a stable 50 mg daily dose of lorundrostat, or a dose-adjusted lorundrostat regimen (starting at 50 mg daily and increased to 100 mg if systolic pressure remained ≥130 mm Hg after 4 weeks).
The primary endpoint was the change in 24-hour average systolic blood pressure at 12 weeks, compared to placebo. A key secondary endpoint assessed this change at 4 weeks in the combined lorundrostat groups.
The key findings were as follows:
- A total of 285 participants were randomized, with 94 assigned to the stable-dose group, 96 to the dose-adjustment group, and 95 to the placebo group. The average age of participants was 60 years, and 53% (150 participants) were Black.
- After 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was −15.4 mm Hg in the stable-dose group, −13.9 mm Hg in the dose-adjustment group, and −7.4 mm Hg in the placebo group.
- The placebo-adjusted change in blood pressure was −7.9 mm Hg for the stable-dose group and −6.5 mm Hg for the dose-adjustment group.
- From baseline to week 4, the placebo-adjusted change in 24-hour average systolic blood pressure in the combined lorundrostat groups was −5.3 mm Hg.
- Potassium levels above 6.0 mmol/L were reported in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and none in the placebo group.
"Lorundrostat demonstrated significantly greater reductions in 24-hour average blood pressure compared to placebo, offering a promising treatment option for patients with uncontrolled and treatment-resistant hypertension," the authors concluded.
Reference:
Laffin LJ, et al "Lorundrostat efficacy and safety in patients with uncontrolled hypertension." N Engl J Med 2025; DOI: 10.1056/NEJMoa2501440.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751